British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis

The Lancet Gastroenterology & Hepatology

Fecha de publicación: July 2020

DOI: https://doi.org/10.1016/S2468-1253(20)30014-5

Autores: Nick Powell, PhD., Hajir Ibraheim, MBBS., Tim Raine, PhD., Richard A Speight, MBBS., Sophie Papa, PhD., Oliver Brain, DPhil., et al.

Background: Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction.